LOS ANGELES & NEW TAIPEI CITY, Taiwan– SyneuRx™ International (TPEX:6575), a global biotech company focused on the development of new classes of drugs for COVID-19 and multiple major central nervous system disorders, today announced it has completed enrollment for its phase 2 clinical trial evaluating the efficacy and safety of SNB01 (‘Pentarlandir’), a novel COVID-19 oral antiviral candidate. In preclinical studies, Pentarlandir demonstrated preliminary efficacy and an excellent safety profile against Omicron, Delta, and previously identified variants of concern in addition to several influenza viruses.
“COVID-19 continues to plague many parts of the world, including individuals who are immunocompromised, unvaccinated or not up to date on vaccines, or who experience breakthrough infection even when vaccinations are up to date,” said Emil Tsai, M.D.-Ph.D., M.A.S., founder and CEO of SyneuRx. “Antivirals that can potentially address multiple variants are much-needed, new tools to combat COVID-19 at a crucial time as new outbreaks continue to emerge.”
In the phase 2 study, 89 participants suffering from unvaccinated or early-stage breakthrough cases of COVID-19 were randomized evenly into high-dose, low-dose, and placebo groups. For the phase 3 study expected to begin in the coming months, an optimal dose will be selected and the scope will expand to evaluate Pentarlandir’s broad-spectrum antiviral activity in inhibiting SARS-CoV-2 as well as influenza viruses, including rigorous safety assessments.
Tsai continued, “Our goal from the start has been to introduce a safe, effective and accessible therapeutic with multiple use cases, including the ability to work against most COVID-19 variants and treat certain influenza strains in order to keep high-risk patients from hospitalization due to the potential ‘twindemic’ caused by COVID-19 and/or influenza.” (IANS)
